Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11199730 | 0.76 | TSHR (0.39) | KIF11BCL2L1BADTSHRCA1 | |
| SCHEMBL2411016 | 0.72 | CYP1A2 (0.32) | — | |
| SCHEMBL15794602 | 0.69 | KIF11 (0.33) | KIF11BCL2L1BAD | |
| SCHEMBL550023 | 0.69 | BCL2L1 (0.36) | KIF11BCL2L1BADTSHRNOS3 | |
| SCHEMBL29853815 | 0.68 | KIF11 (0.49) | KIF11BCL2L1BADTSHR | |
| SCHEMBL322439 | 0.68 | KIF11 (0.49) | KIF11BCL2L1BADTSHR | |
| SCHEMBL2412656 | 0.68 | HPRT1 (0.33) | — | |
| SCHEMBL1278375 | 0.67 | BCL2L1 (0.52) | KIF11BCL2L1BADTSHRNOS3 | |
| SCHEMBL28753848 | 0.67 | KIF11 (0.47) | KIF11BCL2L1BADTSHR | |
| SCHEMBL285402 | 0.67 | CA1 (0.40) | CES1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391704-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-12-07 | — | — | US | claimed |
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-12-02 | — | — | US | claimed |
| EP-3749631-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-12-16 | — | — | EP | claimed |
| CN-111712481-A | Triarylmethane compounds | 三菱瓦斯化学株式会社 | 2020-09-25 | — | — | CN | claimed |
| WO-2019154727-A1 | TRIARYLMETHANE COMPOUNDS | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2019-08-15 | — | — | WO | claimed |
| WO-2019154730-A1 | TRIARYLMETHANE COMPOUNDS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2019-08-15 | — | — | WO | claimed |
| EP-4399199-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | Reuter Chemische Apparatebau e.K. (DE) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399200-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | Mitsubishi Gas Chemical Company, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024115460-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2024-06-06 | — | — | WO | disclosed |
| CN-118043298-A | (Hetero) aryl-substituted bisphenol compound and thermoplastic resin | 罗伊特化学仪器制造公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117940399-A | Heteroaryl or aryl substituted bisphenol compounds and thermoplastic resins | 三菱瓦斯化学株式会社 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024068860-A1 | OLIGOMERIC BINAPHTYL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2024-04-04 | — | — | WO | disclosed |
| US-11931445-B2 | Composition comprising baicalin | L'OREAL (FR) | 2024-03-19 | — | — | US | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012085648-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| EP-2091936-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Purdue Pharma LP (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391704-A1 | TRIARYLMETHANE COMPOUNDS | CBR3, HAX1, HRH3 | KIF11 4078/4885BCL2L1 4110/4885BAD 4206/4885 |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, OPRK1, OPRD1 | KIF11 4425/4885BCL2L1 2262/4885BAD 2631/4885 |
| US-11931445-B2 | Composition comprising baicalin | KRT18, S100A6, DSG1 | KIF11 1023/4885BCL2L1 1005/4885BAD 2707/4885 |
| US-20210371367-A1 | TRIARYLMETHANE COMPOUNDS | CBR3, HAX1, HRH3 | KIF11 4078/4885BCL2L1 4110/4885BAD 4206/4885 |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | TRPV1, TRPA1, TRPV2 | KIF11 4629/4885BCL2L1 3205/4885BAD 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.